XOMA Ltd. (XOMA) today announced that its Phase 2b trial of XOMA 052 in Type 2 diabetes patients did not achieve the primary endpoint of reduction in glycosylated hemoglobin, or HbA1c, after six monthly treatments with XOMA 052 compared to placebo.
“While this trial did not demonstrate glycemic improvement, the potent anti-inflammatory effects and continued positive safety profile reinforce our Phase 3 development program for Behcet’s uveitis, which we anticipate starting this year pending completion of regulatory agency discussions. We are also encouraged by the improvements in C-reactive protein and ‘good’ cholesterol, which support the further evaluation of XOMA 052 in cardiovascular disease and other inflammatory indications,” said Steven B. Engle, XOMA’s Chairman and Chief Executive Officer.
XOMA fell only fractionally to $5.01 in extended trading.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!
Leave a Reply